Holds one valid CEP for glycopyrronium, filing since 2006. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 3 markets.
Holds one valid CEP for glycopyrronium, filing since 2022. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds 3 valid CEPs for glycopyrronium, filing since 2025. Its 2023 FDA inspection closed as NAI, and its GMP is recognised in 16 markets.
Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one valid CEP for glycopyrronium, filing since 2023. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Its 2025 FDA inspection closed as VAI.
Its 2025 FDA inspection closed as VAI.
Holds 2 active US DMFs for glycopyrronium, filing since 2019. Its GMP is recognised in 1 market.
Holds one valid CEP for glycopyrronium, filing since 2026. Its 2018 FDA inspection closed as VAI.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
This page filters the worldwide Glycopyrronium manufacturer list to companies based in India. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free